MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 28, 2006; DOI: 10.1124/mol.106.022715


0026-895X/06/7001-30-40$20.00
Mol Pharmacol 70:30-40, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.022715v1
mol.106.022715v2
70/1/30    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traver, S.
Right arrow Articles by Michel, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traver, S.
Right arrow Articles by Michel, P. P.

The Phenotypic Differentiation of Locus Ceruleus Noradrenergic Neurons Mediated by Brain-Derived Neurotrophic Factor Is Enhanced by Corticotropin Releasing Factor through the Activation of a cAMP-Dependent Signaling Pathway

Sabine Traver, Marc Marien, Elodie Martin, Etienne C. Hirsch, and Patrick P. Michel

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 679, Experimental Neurology and Therapeutics, Paris, France (S.T., E.M., E.C.H, P.P.M.); Université Pierre et Marie Curie, Paris, France (S.T., E.M., E.C.H., P.P.M.); and Pierre Fabre Research Center, Castres, France (M.M., P.P.M.)

We have developed a model system of locus ceruleus (LC) neurons in culture, in which brain-derived neurotrophic factor (BDNF) induces the emergence of noradrenergic neurons attested by the presence of tyrosine hydroxylase (TH) and dopamine-beta-hydroxylase and the absence of phenylethanolamine N-methyl-transferase. Although inactive in itself, the neuropeptide corticotropin releasing factor (CRF) strongly amplified the effect of BDNF, increasing the number of cells expressing TH and the active accumulation of noradrenaline by a factor of 2 to 3 via a mechanism that was nonmitogenic. CRF also acted cooperatively with neurotrophin-4, which like BDNF is a selective ligand of the TrkB tyrosine kinase receptor. The effect of CRF but not that of BDNF was prevented by astressin, a nonselective CRF-1/CRF-2 receptor antagonist. However, only CRF-1 receptor transcripts were detectable in LC cultures, suggesting that this receptor subtype mediated the effect of CRF. Consistent with the positive coupling of CRF-1 receptors to adenylate cyclase, the trophic action of CRF was mimicked by cAMP elevating agents. Epac, a guanine nucleotide exchange factor directly activated by cAMP, contributed to the effect of CRF through the stimulation of extracellular signal-regulated kinases (ERKs) 1/2. However, downstream of ERK1/2 activation by CRF, the phenotypic induction of noradrenergic neurons relied upon the stimulation of the phosphatidylinositol-3-kinase/Akt transduction pathway by BDNF. Together, our results suggest that CRF participates to the phenotypic differentiation of LC noradrenergic neurons during development. Whether similar mechanisms account for the high degree of plasticity of these neurons in the adult brain remains to be established.


Received January 20, 2006; accepted March 23, 2006

Address correspondence to: Dr. Patrick P. Michel, Unité Mixte de Recherche 679, INSERM-UPMC Bâtiment Pharmacie, Hôpital de la Salpêtrière, 47 bd de l'Hôpital, 75013, Paris, France. E-mail: ppmichel{at}ccr.jussieu.fr




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
S. Guerreiro, D. Toulorge, E. Hirsch, M. Marien, P. Sokoloff, and P. P. Michel
Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels
Mol. Pharmacol., October 1, 2008; 74(4): 980 - 989.
[Abstract] [Full Text] [PDF]


Home page
Learn. Mem.Home page
J. N. Gelinas, J. L. Banko, M. M. Peters, E. Klann, E. J. Weeber, and P. V. Nguyen
Activation of exchange protein activated by cyclic-AMP enhances long-lasting synaptic potentiation in the hippocampus
Learn. Mem., May 28, 2008; 15(6): 403 - 411.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. V. Wu, P.-q. Yuan, L. Wang, Y. L. Peng, C.-Y. Chen, and Y. Tache
Identification and Characterization of Multiple Corticotropin-Releasing Factor Type 2 Receptor Isoforms in the Rat Esophagus
Endocrinology, April 1, 2007; 148(4): 1675 - 1687.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics